Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients
A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes
Sponsor: CHRISTUS Health
Terminated
Stopped in December 2007
Other terminated trials from CHRISTUS Health
Other Diabetes Mellitus, Type 1 trials with similar outcome
Listed as NCT00260234, this PHASE1/PHASE2 trial focuses on Diabetes Mellitus, Type 1 and remains terminated or withdrawn. Sponsored by CHRISTUS Health, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CHRISTUS Health
- Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX
- Novocell
For direct contact, visit the study record on ClinicalTrials.gov .